The next generation of BRAF inhibitors into the brain!

ArticleMedicine Guanlan

On November 30th, ABM Therapeutics announced that its self-developed BRAF inhibitor ABM-1310 clinical trial application was approved by the National Medical Products Administration (NMPA), allowing the company to target patients with advanced solid tumors with BRAF mutations Carry out a phase 1 clinical trial

ABM-1310 is an innovative small molecule drug independently developed by Bichen Pharmaceutical.

ABM-1310, developed by Bichen Pharmaceutical, has shown its ideal advantages in blood-brain barrier penetration in pre-clinical studies

Currently, the Phase 1 clinical trial of ABM-1310 is proceeding smoothly in the United States, and the initial data has shown good safety and positive information

Reference materials:

[1] The BRAF inhibitor ABM-1310 IND of Bichen Pharmaceutical was approved by China National Medical Products Administration.

[2] ABM Therapeutics will appear at the 2020 American Society for Cancer Research Annual Meeting.